Monday Apr 14
Applied Clinical Trials
Arena Pharmaceuticals Reports Eisai's Launch of National Television...
Arena Pharmaceuticals Reports Eisai's Launch of National Television Advertising Campaign for BELVIQ? CIV for Chronic Weight Management Arena Pharmaceuticals Reports Eisai's Launch of National Television Advertising Campaign for BELVIQ CIV for Chronic Weight Management /PRNewswire/ -- Arena Pharmaceuticals, Inc. today reported that Eisai Inc. has ... (more)
Epizyme Granted Patent Covering Diagnosis And Treatment Of Cancers Associated With EZH2 Mutation
8,691,507 with claims that cover the identification of patients carrying EZH2 oncogenic mutations as candidates for treatment with EZH2 inhibitors.
Zalicus Inc.To Present At American Association for Cancer Research 2014 Annual Meeting
Zalicus Inc. , a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that a poster developed in collaboration with colleagues from Eisai Inc. and a podium presentation with collaborators from Sanofi will be given at the American Association for Cancer Research 2014 Annual Meeting ... (more)
Press release distribution, EDGAR filing, XBRL, regulatory filings
ETS2101 well tolerated with no serious adverse events. Early evidence of possible hal...
Eisai Assigns Its Worldwide Exclusive License for DACOGENA to Otsuka
We give our first thoughts to patients and their families, and helping to increase the benefits health care provides.
Otsuka Acquires Rights to Hematological Cancer Treatment Dacogen from Eisai
Otsuka has acquired rights from Eisai Inc. to develop and sell in the US, Canada and Japan the DNA methylation inhibitor Dacogen A .